The pharmacokinetics of S-warfarin in healthy subjects carrying different CYP2C9 genotypes.

被引：0
|
作者：
Shaoul, H. [1 ]
Blotnick, S. [1 ]
Muszkat, M. [1 ]
Caraco, Y. [1 ]
机构：
[1] Hadassah Univ Hosp, Jerusalem, Israel
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2008年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S19 / S19
页数：1
相关论文
共 50 条
  • [21] Effect of CYP2C9 polymorphism on the pharmacokinetics of candesartan in healthy Korean subjects.
    Lee, Seok-Yong
    Bae, Jung-Woo
    Han, Ho-Kyun
    Kim, Nam-Tae
    Lee, Jin-Hee
    Jang, Choon-Gon
    Jung, Dong-Won
    Lee, Hwan-Joo
    Choi, Sun-Ok
    Kim, Ok-Hee
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 235 - 235
  • [22] Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam
    Perini, JA
    Vianna-Jorge, R
    Brogliato, AR
    Suarez-Kurtz, G
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (04) : 362 - 369
  • [23] Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects
    Huang, Hang-Xing
    Wu, He
    Zhao, Yingying
    Zhou, Tao
    Ai, Xin
    Dong, Yu
    Zhang, Yan
    Lai, Yong
    XENOBIOTICA, 2021, 51 (05) : 616 - 623
  • [24] Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects
    Li, Z.
    Wang, G.
    Wang, L. -S.
    Zhang, W.
    Tan, Z. -R.
    Fan, L.
    Chen, B. -L.
    Li, Q.
    Liu, J.
    Tu, J. -H.
    Hu, D. -L.
    Liu, Z. -Q.
    Zhou, H. -H.
    XENOBIOTICA, 2009, 39 (10) : 788 - 793
  • [25] Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-Warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers
    Ma, JD
    Nafziger, AN
    Kashuba, ADM
    Kim, MF
    Gaedigk, A
    Rowland, E
    Kim, JS
    Bertino, JS
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (06): : 570 - 576
  • [26] Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug–drug interaction studies for CYP2C9
    Kerenaftali Klein
    Ivelina Gueorguieva
    Leon Aarons
    Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39 : 147 - 160
  • [27] 5′-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients
    Takahashi, H
    Ieiri, I
    Wilkinson, GR
    Mayo, G
    Kashima, T
    Kimura, S
    Otsubo, K
    Echizen, H
    BLOOD, 2004, 103 (08) : 3055 - 3057
  • [28] Novel CYP2C9 promoter polymorphisms are associated with lower S-warfarin clearance and dose requirements in patients
    Cavallari, L. H.
    Vaynshteyn, D.
    Freeman, K. M.
    PHARMACOGENOMICS, 2014, 15 (03) : 262 - 262
  • [29] Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
    Kang, Pureum
    Cho, Chang-Keun
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    Choi, Chang-Ik
    Bae, Jung-Woo
    ARCHIVES OF PHARMACAL RESEARCH, 2023, 46 (05) : 438 - 447
  • [30] Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
    Pureum Kang
    Chang-Keun Cho
    Choon-Gon Jang
    Seok-Yong Lee
    Yun Jeong Lee
    Chang-Ik Choi
    Jung-Woo Bae
    Archives of Pharmacal Research, 2023, 46 : 438 - 447
12345